Related Experiment Video
Updated: Mar 25, 2026
09:04
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
49.3K
[Use of NSAIDs in inflammatory bowel disease]
Vivica Dharmadasa1, Marjo Kapraali2, Nathalie Peira3
1-doktorand, specialistläkare, gastroenterologi och hepatologi, ME övre buk, -Karolinska -universitetssjukhuset, -Stockholm; institutionen för medicin, Solna, Karolinska institutet.
Lakartidningen
|March 24, 2026
Summary
Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) appears to pose a minimal risk of flare-ups for patients with well-controlled inflammatory bowel disease (IBD). However, current evidence is limited and uncertain.
Area of Science:
- Gastroenterology
- Pharmacology
- Health Technology Assessment
Background:
- Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, frequently causes pain, impacting daily function and quality of life.
- Effective pain management is essential for IBD patients.
- Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain relief, but concerns exist regarding their potential to trigger IBD flare-ups.
Purpose of the Study:
- To systematically review the risk of NSAID-induced flare-ups in patients with inflammatory bowel disease (IBD).
- To evaluate the current evidence regarding NSAID use in IBD patients and inform clinical guidelines.
Main Methods:
- A systematic review was conducted by Health Technology Assessment (HTA) Region Stockholm.
- The review synthesized data from existing studies on NSAID use and IBD flare-ups.
Main Results:
- Short-term NSAID use is associated with a minimal or negligible increase in the risk of IBD flare-ups in patients with well-controlled disease in remission.
- The certainty of these findings is limited due to insufficient data and methodological weaknesses in the included studies.
Conclusions:
- While short-term NSAID use may be relatively safe for IBD patients in remission, the evidence remains uncertain.
- Further high-quality research is needed to definitively establish the risk associated with NSAID use in IBD patients.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
01:29Inflammatory Bowel Disease IV: Pharmacological Management
917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
917
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
728
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
728
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K